Satellos Bioscience Inc.
TSX:MSCL.TO · Toronto Stock Exchange
+$0.01 today
Vol 0.00M · Avg 0.02M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-91.3%
avg -21.5%
ROIC
-97.1%
avg -101.1%
ROA
-79.5%
avg -176.1%
Analysis
ROA is currently the strongest return metric at -79.5% versus its period average of -176.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Francis Gleeson | Co-Founder, Chief Executive Officer, President & Director | $918,853.00 | — | 71 | — | — |
Philip Lambert | Chief Scientific Officer | $802,233.00 | — | 57 | — | — |
Elizabeth Williams | Chief Financial Officer & Corporate Secretary | $678,930.00 | — | 48 | — | — |
Wildon Farwell | Chief Medical Officer | $405,233.00 | — | 50 | — | — |
Warren Whitehead | Head of Corporate Strategy | $313,540.00 | — | 74 | — | — |
Michael A. Rudnicki | Co-Founder & Chief Discovery Officer | $120,000.00 | — | 64 | — | — |
Michael Liggett | Strategic Advisor | $44,483.00 | — | 66 | — | — |
Ryan Mitchell | Senior VP & Head of Corporate Development | — | — | — | — | — |
J. Robert Hall | Senior Vice President of Finance & Administration | — | — | — | — | — |
Desiree Chan | Chief of Staff | — | — | — | — | — |
Antoinette Paone | Chief Development Officer & Head of Regulatory Affairs | — | — | 47 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Quipt Home Medical Corp.
QIPT.TO
$221.44M
Cannara Biotech Inc.
LOVE.V
$181.03M
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
BioSyent Inc.
RX.V
$160.02M
Cybin Inc.
CYBN.NE
$157.10M
Grown Rogue International Inc.
GRIN.CN
$149.96M
Helix BioPharma Corp.
TSX:HBP.TO
$108.46M
Zentek Ltd.
ZEN.V
$62.38M
Sernova Corp.
TSX:SVA.TO
$53.90M
Medicenna Therapeutics Corp.
MDNA.TO
$28.87M
Who manages MSCL.TO?
Satellos Bioscience Inc. (MSCL.TO) lists 11 active executives. The top listed executive is Wildon Farwell, Chief Medical Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.